Pfizer decides to continue manufacturing atorvastatin at Little Island, Ireland site

Pfizer confirms that due to continued increase in projected atorvastatin demand for the foreseeable future, Pfizer has determined that it is important to continue manufacturing atorvastatin in Little Island.

While this decision is mainly driven by volume increases for atorvastatin, Little Island's demonstrated commitment and continued excellence in the manufacturing fundamentals – Safety, Quality, Supply and Cost – was also a factor.  As usual, Pfizer will continue to review its ongoing strategic supply needs.

"The global manufacturing environment is very competitive and our colleagues have been key in helping drive the fundamentals that have enabled us to achieve greater competitiveness during the past few years, said Seamus Fives, Site Leader, Little Island and Ringaskiddy.  "The Little Island site has continued to demonstrate the highest levels of performance, flexibility and commitment to the work we are doing here and I am proud of what has been achieved.  It is an example of how continuing to focus on competitiveness and adding business value generates business opportunities."


Background

In May of 2013, Pfizer announced plans to consolidate manufacturing operations in Ireland and exit the Little Island site.  At that time we expected to be fully out of Little Island by August of 2014.  In mid-2014, due to an unexpected increase in atorvastatin demand, the initial Little Island facility exit was revised to 3Q of 2015.

·         The proposals set forth in this message are subject to compliance with all local legal and regulatory obligations, including the obligation to inform and/or consult with labour organizations, works councils, trade unions and employee representatives.

 

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.